Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 116

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 2
Chunk 116
---
 improvements in response and remission rates for patients with MDD, compared to treatment as usual.

•Effective August 16, 2025, Benjamin R. Wheeler was appointed Chief Financial Officer. 

Results of Operations for the Three Months Ended September 30, 2025 and 2024

The results of operations for the three months ended September 30, 2025 and 2024 are discussed below.  

Revenue

The following table summarizes year-over-year revenue changes in our core product categories:

Three months ended September 30,% of Total Revenue(in millions)20252024Change20252024Hereditary Cancer$93.0 $90.5 $2.5 45%43%Tumor Profiling29.5 31.6 (2.1)14%15%Prenatal44.5 43.5 1.0 22%20%Pharmacogenomics38.7 47.7 (9.0)19%22%Total revenue$205.7 $213.3 $(7.6)100%100%

The following table summarizes volume changes in our core product categories:

Three months ended September 30,(in thousands)20252024% ChangeVolume:Hereditary Cancer82 74 11 %Tumor Profiling12 13 (8)%Prenatal155 162 (4)%Pharmacogenomics137 127 8 %Total386 376 3 %

Revenues decreased $7.6 million for the three months ended September 30, 2025 compared to the same period in the prior year primarily due to $8.6 million of revenue recognized during the three months ended September 30, 2024 for tests in which the performance obligation was met in a prior period. For the three months ended September 30, 2025, revenue for tests in which the performance obligation was met in a prior period was immaterial. 

Pharmacogenomics revenues decreased $9.0 million for the three months ended September 30, 2025 compared to the same period in the prior year due to a 25% year-over-year decrease in average revenue per test, due to revenue recognized for the three months ended September 30, 2024 for tests in which the performance obligation was met in a prior period and UnitedHealthcare's change in GeneSight test coverage under its commercial, individual exchange, and certain managed Medicaid benefit plans. We expect this